The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | Epigenetic targeting and therapeutic potential of UVI5008 in CLL
Carmela Dell’Aversana, PhD, LUM University, Bari, Italy, discusses the epigenetic activity of UVI5008 in chronic lymphocytic leukemia (CLL), highlighting its ability to selectively reprogram chromatin and suppress BTK transcription. She explores how this dual enzymatic and epigenetic mechanism may offer therapeutic advantages in relapsed or refractory disease, including activity in TP53-altered CLL. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
